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1Introduction
 Biotechnology research has much to promise human society.  Beyond the 
obvious benefits of being able to clone rare animal species or potentially to 
revitalize extinct species1, there are many practical applications that are 
beneficial to human society directly.  Rare blood types might be created from 
specialized stem cells.  The tragedies of Christopher Reeve and others like him 
who have suffered paralysis from spinal cord trauma may be reversible by using 
stem cells to replenish damaged and severed nerve cells in the spinal column.2
The dire shortage of organs for those needing transplants can be reduced by 
creating an organ designed specifically from the patient’s stem cells in a lab 
setting to guarantee acceptance by the patient’s body.3  Israeli scientists several 
years ago have already coaxed stem cells into pulsating like a heartbeat.4  The 
day is very near when badly needed organs will seemingly be created from 
1
 If you have not already, rent Steven Spielberg’s Jurassic Park to get the idea.  But for a more 
mundane application go to Google.com/news and type stem cells, or go to CBSNews.com and do 
a website search for stem cells.  CBS has at least 20 articles written on stem cells and their 
application, most of which are dated no earlier than 2000.  
2
 Damon J. Whitaker, Note: The Patentability of Embryonic Stem Cell Research Results, 13 J. 
LAW & PUB. POL’Y 361, 365 (citing National Cancer Institute, Institutes and Centers Answers to 
the Question: “What Would You Hope to Achieve From Human Pluripotent Stem Cell Research?,” 
at http://222.nih.gov/news/news/stemcell/achieve.htm (Apr. 26, 2000)); see also John Bogatko, 
Stem Cell Research: A Comparative Legal Analysis, 6 J. MED. & LAW 123, 126 (2002) (citing
Vanessa Lu, Spine Tissue Discovery Could Help Injury Victims; Plastic Tube Connects Tissue, 
TORONTO STAR, Aug. 29, 2001, at A01; and David N. Leff, Science Scan is a ‘First’, Israelis Use 
Human Embryonic Stem Cells to Create Heart-Like Beating Muscle Cells, BIOWORLD TODAY, Aug. 
6, 2001).   On the 23rd of May CBSNews.com reported that scientists were able to partially repair 
damaged nerve cells in mice through stem cell injections.
3
 Whitaker, supra note 2 at 365 (citing Remarks by President George W. Bush on Stem Cell 
research, at http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html (Aug 9, 2001)), 
National Institute of Health, Stem Cells: A Primer 1, available at
http://www.nih.gov/news/stemcell/primer.htm (May 2000)). 
4
 Taiwo A. Oriola, Article: Ethical and Legal Issues in Singapore Biomedical Research, 11 Pac. 
Rim L. & Pol’y 497, 519 (citing Tim Radford, Stem Cells Turned into Heart Tissue, GUARDIAN 
UNLIMITED, Aug. 2, 2001, http:/www.guardian.co.uk/genes/article/0,2763,530902,00.html.).
2wholecloth to replace dying or diseased ones.5  Damaged skin from fires and 
accidents can be replaced with skin tissue that is grown in the lab from the 
patient’s own stem cells; perhaps even severely scarred tissue from fires can be 
healed by injecting the damaged skin with potent stem cells. More recently, a 
young boy who had the fatal Krabbe disease (a progressive and swift genetic 
disorder that leads to fatal deterioration of the central nervous system)6 was 
given a fighting chance of living beyond the 2 year life expectancy of those who 
suffer from this disease.7 Additionally, the stem cell transplant has been so 
successful that now his brain is producing 100 percent donor stem cells and his 
brain should at least partially recover in four to six months.8
If the potential is so great with stem cell research, then what is all the 
opposition and controversy for?  There are many factors.  If one thinks about how 
biotechnological innovations have made what was once relegated to the creative 
world of science fiction, then concern begins to mount.  Simply thinking about 
how the Third Reich of Nazi Germany performed horrendous scientifically based 
studies on humans sends a chilling reminder of the need for ethics and morality 
to step in at some point in scientific research.  The question becomes however at 
what point and through which mechanisms.  The United States of America and 
5
 John Bogatko, Stem Cell Research: A Comparative Legal Analysis, 6 J. MED & LAW 123 (citing 
Neil Munro, Patents, Profits, and the Stem-Cell Debate, 33 THE NAT’L J. 32 (2001); Ian Wilmut & 
Lesley A. Paterson, Can it be Unethical to Heal the Sick?, THE TIMES HIGHER EDUC. SUPPLEMENT, 
Aug 17, 2001, at 19; and James S. Grisoia, Stem Cell grafting for Epilepsy; Clinical Promise and 
Ethical concerns, 2 EPILEPSY & BEHAV. 318, 319 (2001)); and id.
6
 Eunice Kim, Tiny Struggle: Mendon Neighbors Rally to Support Toddler’s Fight for Life, METRO 
WEST DAILY NEWS,  May 16, 2004, available at: 
http://www.metrowestdailynews.com/localRegional/view.bg?articleid=68469.
7 Id.
8 Id.
3the European Union have come up with bipolar approaches to this question and 
this will be addressed below.  The stem cell controversy is based on more than 
the wild fantasies of science fiction writers and the horrors of cruel, vile 
government experiments.  The controversy enters into other moral and ethical 
concerns that are more strongly grounded in our present reality. 
Stem Cells:  what are they, what are their benefits, what is the controversy?
A basic understanding of stem cells and ontogeny is necessary to see the 
source of the ethical controversy surrounding stem cells. The human body is 
composed of hundreds of millions of cells9, all derived from a single cell, that is 
formed when a male’s gamete (sperm) fuses during fertilization with a female’s 
gamete (egg).10 Each gamete only contains half of the necessary commands for 
the assembly of a single cell; hence, the name haploid. Upon union with sperm 
and egg, the newly formed diploid cell, called a zygote, undergoes a series of 
divisions.11  The cell that is formed upon the union is undifferentiated and has all 
the necessary commands for the 200 or so different types of cells in the human 
body.12
Not all cells are alike.  We have around 200 different types of cells in the 
human body.13  Contrary to popular myth, most human cells do not have the 
9
 Whitaker, supra note 2 at 363 (citing Gerald J. Tortora & Sandra Reynolds Grabowski, 
Principles of Anatomy and Physiology 7 (8th ed. 1996)). 
10 Id.  (citing id.). 
11
 Whitaker, supra note 2, at 364 (citing Tortora &Grabowski, supra note 6, at 80-83)
12
 Meredith Mariani, Note: Stem Cell Legislation: An International and Comparative Discussion, J. 
OF LEG. 379, 381 (citing House of Lords, Select Committee on Stem Cell Research Report, 
Chapter 2, at http://www.publications.parliament.uk/1.htm (Feb. 13, 2002) (on file with author)). 
13 Id.
4ability to divide.14  Stem cells are the cells that replace damaged or dying 
specialized cells.15  Though specialized or differentiated cells perform a specific 
function, they contain the exact genetic code of the original cell which was 
formed when the sperm fused with egg upon fertilization.  However, the 
expression of certain functions is turned off and seemingly is never able to be 
turned back on (at least naturally, scientists have experimented with ways to 
reactivate certain functions).
During the first five days the zygote undergoes a series of critical cell 
divisions.16  These cells are totipotent, meaning that they have the ability to 
become any cell and to divide and specialize to become a human being.  In fact,
cloning is based on taking the cells from this point in the division process. After 
five days the embryo forms a blastocyst, which is the structure that is made up of 
two types of cells: fetal and embryonic.17  The fetal stem cells in the outer layer of 
the blastocyst are limited to becoming any type of fetal cell, while the embryo 
stem cells in the inner layer of the blastocyst have the ability to become any type 
of cell, except fetal cells.18  The embryonic stem cells are pluripotent, which 
means that they can become any type of cell, except fetal stem cells.19  From this 
point to about 14 days when the nerve streak forms the embryonic stem cells 
14
 Mariani, supra note 10, at 381 (citing House of Lords, Select Committee on Stem Cell 
Research report, chapter 2 § 2.2, at http://www.publications.parliament01.htm (Feb. 13, 2002) (on 
file with author)).
15 Id.
16 Id. at 382 
17
 Whitaker, supra note 2, at 364 (citing National Institute of Health, supra note 2).
18 Id.
19 Id; see also Bogatko, supra note 2 at 126-27 (citing THE NAT’L BIOETHICS ADVISORY COMM’N, 
ETHICAL ISSUES IN HUMAN STEM CELL RESEARCH, VOLUME 1, REPORT AND RECOMMENDATIONS OF 
THE NATIONAL BIOETHICS ADVISORY COMMISSION, at i (1999)).
5may be tapped into for their pluripotency.20  Upon the beginnings of the formation 
of the nervous system, the embryonic stem cells lose their potency as they 
continue to specialize and differentiate toward adult stem cells.21  Adult stem 
cells are specialized stem cells that are located in bone marrow, muscle tissue, 
blood, the brain, etc.22  Each type is specialized and replaces a limited type of 
cells.  For instance the stem cells in the muscles are limited to just replenishing 
damaged or dying specialized muscle cells.  Therefore, the adult stem cells are 
multipotent, in that they have a multitude of cells that they can specialize into, but 
they are limited to a much smaller range of cell types.23
The metaphysical debate24
 The first controversy concerning stem cell research is the metaphysical
debate over when life begins.  The problem with embryonic stem cell research is 
that when pluripotent embryonic stem cells are removed from an embryo the 
embryo is entirely destroyed.  The life essence that might have been, no longer 
can be.  As was stated supra it is only before the blastocyst is formed that the 
individual stem cells have the potential to develop into a human being. Therefore, 
at that stage one could conceivably duplicate the same being.  This in itself has 
its own moral and ethical questions that are outside of the scope of this paper.
20
 Cyril R. Vidergar, Comment: Biomedical Patenting: Permitted, but Permissible?, 19 SANTA 
CLARA COMPUTER & HIGH TECH. L.J. 253, 254 (2002); and Bogatko, supra note 2, at 138.
21 See generally Bogatko, supra note 2, at 126-27; Mariani, supra note 11, at 381-85.
22 See generally Mariani, supra note 11, at 384.
23 Id.
24
 For an argument engaging in the metaphysical debate to justify stem cell research see Michael 
Kinsley, The False Controversy of Stem Cells: If You Think it Through, the Case for Embryonic 
6However, focusing on the embryonic stem cell, we can see that once a stem cell 
is pulled the entire potential for an independent life is destroyed.  This brings 
questions of religion, morals and ethics into the center of the debate.
 As is evidenced by the furor and divisiveness of the abortion issue, there 
has been no answer to the metaphysical debate over when human life and 
human consciousness begins.  As such, research on embryos, even if in their 
earliest stages, is extremely controversial.  In 2001, President George Bush tried 
to reach a balance between two of his most powerful and active bases, the 
conservative Christian Coalition and his base of doctors, scientists and 
medical/pharmaceutical businesses.25  First, he allowed embryo research to 
continue to be funded if they were part of a limited supply of already obtained 
embryos for in vitro fertilization that were not going to be used, and hence they 
would be destroyed anyway.26  Second, Bush has taken an approach similar to 
the abortion issue. While the government allows abortions, states are left to 
decide whether they will subsidize abortions.  In this vein Bush has allowed 
researchers to experiment on embryonic stem cells, but if they use embryonic 
stem cells that are not part of the limited government stockpile, then they will lose 
government funding.
Research is an Easy One, TIME MAGAZINE, 31 May 2004, available at: 
http://www.time.com/time/magazine/article/0,9171,1101040531-641157,00.html
25
 For a nice overview of these issues see Ease Stem Cell Restrictions, THE LEDGER, available at: 
http://www.theledger.com/apps/pbcs.dll/article?AID=/20040508/NEWS/405080390/1036.
26 See Bogatko, supra note 2, at 142 (citing The Presidency: The Meaning of Stem Cells, TIME, 
Aug 20, 2001, at 14); see also id. at 127n.25
7While this may sound like a happy compromise, it is very important to note 
that the government funds 28 billion dollars a year on scientific research.27  The 
threat to withdraw funding based on certain activities, is actually quite prohibitive 
to researchers.  And some states, realizing this, have started to consider 
legislation to fund stem cell research.28  Additionally, great discoveries have been 
found through privately funded research. On the other hand, perhaps these very 
restrictions on embryonic stem cell prohibition will entice researches to develop 
other technologies that will coax differentiated and specialized cells into 
becoming undifferentiated pluripotent cells or provide incentive to seek other 
potential avenues. More recently, there have been some very positive results 
from adult stem cell research.29 There are currently two additional possibilities.  
The first alternative is through using an unfertilized egg, gutting it out and 
replacing it with the insides of any cell in the human body.30  Another option, 
though only with a 1/100th success rate is to isolate cells from the human body 
and put them in a supportive laboratory environment, and then starve the cell.
Typically 1/100 cells will survive, but in a less differentiated form, enabling 
27
 For information on a more recent bi-partisan move to increase federal funding see Stem Cell 
Research: Policy and Politics, NATIONAL PUBLIC RADIO, available at: 
http://www.npr.org/features/feature.php?wfId=1891207 (last visited May 25, 2004).
28
 Stephanie Chavez, Stem Cell Funding is Put in the Spotlight, LOS ANGELES TIMES, available at: 
http://www.latimes.com/news/local/state/la-me-nancy9may09,1,111714.story?coll=la-news-state
29
 For an interesting article highlighting the dangers of embryo stem cell research and highlighting 
the benefits of adult stem cell research see Wesley Smith, Adult Stem Cell Research More 
Effective than Embryonic Cells, LifeNews.com, 25 May 2004, available at: 
http://www.lifenews.com/bio302.html; see also Matters of Life and Death: Scientist in Stem-Cell 
Cover-Up, Deliberately Exaggerate Embryonic Advances, Ignore Adult, available at: 
http://worldnetdaily.com/news/article.asp?ARTICLE_ID=38633, 25 May 2004.
30 See Bogatko, supra  note 2, at 128 (citing Mark Nichols, Stem Cells, A Moral Dilemma, 
MACLEAN’S, Aug. 27, 2001, at 44); see also Mariani, supra note 11, at 385 (citing H.R. Rep. No. 
107-170, at http://www.house.gov/judiciary/legreports.htm (July 27, 2001)).
8scientists to use these less potent and costly cells to bypass all the ethical and 
moral questions. 
Stem Cells and US Patent Law.
Now that we have examined the complexity of stem cells, the 
political/policy debates concerning stem cells, and covered what they are, let us
now consider stem cells and patent law in the US.  The US patent system—in
fact almost any patent system--is aimed at benefiting the public.  In theory,
patents work by providing the inventor an incentive to invent in the first place and 
then to disclose.  Disclosure to the public is rewarded by giving the inventor a 
monopoly.  Striking the right balance between incentive and public access 
creates a tension that must be carefully balanced.  A system that does not give 
the inventor a long enough monopoly creates a system that lacks a strong 
incentive to invent, especially in regards to things that are costly to invent.  A 
system that gives the inventor too long of a monopoly, burdens society, by 
preventing the free market system to step in and provide a price that is in 
balance with the supply and demand. 
The United States has peculiar laws relative to the rest of the 
industrialized world in many regards.  However, as the world’s only remaining 
super power and as the country with the most prolific patent system in the world 
it is important in creating an international patent regime to keep in mind that 
perhaps the US system is so successful because it contains some essential 
traits.
9In the US the tension between incentive for inventors and access by 
society is carefully balanced by the United States Patent Act of 1952 which 
stipulates four requirements for one to get a patent.31  This right to exclude is for 
20 years from the date of the filing of the application.  There are three types of 
patents categories in the US:  utility, design, and plant patents.32 There are two 
dominant utility patents:  process patents and product patents.33  Process patents
prevent others from using a particular process without compensation.34
However, in process patents, an inventor can create another means to reach the 
same ends.35 On the other hand a product utility patent  prevents one from using 
or creating the patented product whether or not a different process was utilized.36
Typically, biotechnology inventions fall within the stipulated language of utility 
patents: “whoever invents or discovers any new and useful process, machine, 
manufacture, composition of matter, or any new and useful improvement thereof, 
may obtain a patent therefor.”37 There are four requirements for a utility patent: 
31 See generally Qin Zhang, Notes and Comments: Patent Law and Biotechnology: A Proposed 
Global Solution for the Public and the Biotechnology Industry, 9 SW. J.L. & TRADE AM. 195 (2002-
03); James J. Muchmore, Article: Proprietary Rights and the Human Genome project:  A Legal 
and Economic Perspective, 8 DIGEST 45 (2000); Mattias Luukkonen, Note: Gene Patents: How 
Useful are the New Utility Requirements?, 23 T. JEFFERSON L. REV. 337 (2001);  May Mowzoon, 
Comment: Access Versus Incentive: Balancing Policies in Genetic Patents, 35 ARIZ. ST. L.J. 1077 
(2003); Michael John Gulliford, Comment: Much Ado about Gene Patents: The Role of 
Foreseeability, 34 SETON HALL L. REV. 711 (2004); Matthew Erramouspe, Comment: Staking 
Patent Claims on the Human Blueprint: Rewards and Rent-Dissipating Races, 43 UCLA L. Rev 
961 (1996); Courtney J. Miller, Comment: Patent Law and Human Genomics, 26 CAP. U.L. REV.
893 (1997); Cyril R. Videgar, Comment: Biomedical Patenting: Permitted, but Permissible?, 19
SANTA CLARA COMPUTER & HIGH TECH. L.J. 253 (2002).
32 See Erramouspe, supra note 23, at 966 (citing Thomas G. Field, Jr., Brief Survey of Intellectual 
Property, 31 IDEA 85, 91-92 (1990)).
33 Id. (citing id.).
34 Id. (citing id.).
35 Id. (citing id.).
36 Id. (citing id.).
37
 35 U.S.C. § 101
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utility/usefulness, novelty, non-obviousness, and disclosure.38
Under US law, “any new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof” are 
patentable.39 Besides usefulness, novelty is a prerequisite for a utility patent.  
Before one can obtain a patent, the idea must be new. In addition, “a patent may
not be obtained…, if the differences between the subject matter sought to be 
patented and the prior art are such that the subject matter as a whole would have 
been obvious at the time the invention was made to a person having ordinary 
skill in the [relevant] art.”40 Finally, one must make a sufficient disclosure so that 
“one skilled in the art” can practice the invention. 41
Article I, Section 8, Clause 8 of the US Constitution states that the 
government is “to promote the Progress of Science and Useful Arts, by securing 
for limited Times to Authors and Inventors the exclusive Right to their respective 
Writings and Discoveries.”  Congress has from time to time enacted patent 
regulation to carry out this constitutional mandate.  The current US patent regime
was created in 1952, well before biotechnology was even on the minds of most 
congressmen.   Although the US patent system does not deal with the morality of 
patents, to be patent eligible the application must fall within patentable subject 
matter.42
The founding fathers wanted a system that would reward creativity and 
38 Id.
39 Id.
40
 35 U.S.C. § 103
41
 35 U.S.C. § 112
42
 35 U.S.C. §§ 100-01
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invention.  They realized that things would change over time; that situations 
would change over time.  Just as they allowed for the Constitution to be flexible 
to adapt and change to unforeseen happenings and situations, so too did they 
give Congress the power to create a patent system that was flexible enough to 
adapt to unforeseen technologies.  
Stem cells are one of many new advances in technology that our flexible 
patent system has adapted to.43 The courts for a time struggled with the new 
biotechnologies, seemingly wavering on incorporating the moral utility doctrine 
into our system.44  Fortunately, the courts moved away from that. In the 
human/animal Chimera case; the courts decided to stay away from the moral 
utility doctrine and instead rejected his patent on account of the post civil war 
amendments.45
Stem cells are as controversial in their own right as abortion for many of 
the same reasons.  Currently, the US and other industrialized nations are trying 
to negotiate a world patent regime that incorporates the current universal 
43 see generally Erramouspe, supra note 33, at 966-70; Gulliford, supra note 33, at 722; 
Summers, supra note 33, at 484-85 &505-09; Farrell, supra note 33, at 520-530; Lacy, supra note 
33, at  788-91; Videgar, supra note 33, at 256-65; Linda J. Deaine and Aaron Xavier Fellmeth, 
Reinventing the Double Helix: A Novel and Nonobvious Reconceptualization of the Biotechnology 
Patent, 55 STAN. L. REV. 303, 312-320; Zhang, supra note 33, at 198-202; Luukkonen, supra note 
33, at 345-48; Muchmore, supra note 33, at 50-53.
44 See Benjamin D. Enerson, Note: Protecting Society From Patently Offensive Inventions: the 
Risk of Reviving the Moral Utility Doctrine, 89 CORNELL L. REV. 685, 690-94) (Mr. Enerson 
skillfully shows a general trend away from Justice Story’s assertion that for something to be 
useful it must not be immoral and a significant move towards a patent system that does not 
consider morality at all.  Additionally, Mr. Enerson notes that the Revised Interim Utility Guidelines 
Training Materials of the United States Patent and Trademark Office necessitates specificity, 
substantiality, and credibility in utility.  He notes that there is not mention concerning moral utility).
45 See Thomas A. Magnani, The Patentability of Human-Animal Chimeras, 14 BERKELEY TECH 
L.J. 443, 452, 1999).  In the Chimera case, though leaning towards stating that the issuance of a 
patent would violate public morals, the USPTO rejected the patent application concluding that 
Congress when it created the 1952 Patent Act it did “not intend to allow patents on humans or on 
12
application patent procedures to a substantive universal patent regime.  However 
there are key stumbling blocks that need to be addressed.  Stem cells in 
particular and biotechnology in general have thrown many challenges to our 
patent system, to Europe’s patent system as well as to the patent systems of the 
industrialized countries of the world.  
European patent law and stem cells.
The European Union’s patent system has some starkly different rules and 
regulations regarding patents.  Central to these differences is the The European 
Patent Convention’s (hereinafter “EPC”) statutory moral utility doctrine.  On 
account of the differing structures and level of use of the moral utility doctrine, the 
US and EU responded differently to biotechnological innovations in general and 
stem cell research in particular.46  In fact, the US system adapted more readily 
and actually promoted biotechnological innovation, whereas the EU system 
seemed for a time to stifle it.   Even today, many in Europe wonder if they struck 
the right balance via the Council Directive 98/44 on the Legal Protection of 
creatures that are essentially human.”  (Press Release, U.S. Patent and Trademark Office (April 
1, 1998), available at http://www.upto.go/web/offices/com/s06.htm).
46
 See generally Teresa M. Summers, Note: The Scope of Utility in the Twenty-First Century; New 
Guidance for Gene-Related Patents, 91 GEO. L.J. 475 (2003); Enerson, supra note 47; Jasemine 
Chambers, Patent Eligibility of Biotechnological Inventions in the United States, Europe and 
Japan:  How Much Patent Policy is Public Policy?, 34 GEO. WASH INT’L L. REV. 223 (2002); Taiwo 
A. Oriola, Article: Ethical and Legal Issues in Singapore biomedical Research, 11 PAC. RIM L. & 
POL’Y 497 (2002); Timothy Caulfield, A Colloquy on the Romanow Report: Sustainability and the 
Balancing of the Health Care and Innovation Agendas: The Commercialization of Genetic 
Research, 66 SASK. REV. 629 (2003); Lorelei Perez Westin, Notes and Comments: Genetic 
Patents: Gatekeeper to the Promised Cures, 25 T. JEFFERSON L. REV. 271 (2002); David Korn 
and Stephen J. Heinig, Public Versus Private Ownership of Scientific Discovery: Legal and 
Economic Analysis of the Implications of Human Gene Patents, 77.12 ACADEMIC MEDICINE 1301 
(2002); and Kate Murashige, Patents and Research—An Uneasy Alliance, 77.12 ACADEMIC 
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biotechnological Inventions (hereinafter “Directive 98/44/EC”), which was an 
attempt to reign in the EPC’s strong codified moral utility doctrine.
The EPC provides inventors the opportunity to apply simultaneously for 
patents in numerous EU countries.  The EPC centralizes the application process.  
However, patent infringement and enforcement challenges must be brought 
within the nation in which the violation occurs.47
Article 52 of the EPC establishes four prerequisites for a patent to be 
issued: 1) it must be an invention, 2) it must be novel, 3) it must have inventive 
activity, and 4) it must have industrial application.48  There was controversy in the 
EU over whether biotechnological innovations were patentable.  Article 6 of the 
EPC states that inventions must not violate ordre public or morality.49  If they do, 
then citizens are given standing to show that it violates ordre public or morality 
and can block the issuance of the patent.
In many EU member states, unlike the US there are laws prohibiting 
certain biotech inventions from being patented.50  The US system is different 
from the EU system in that the US system has classes of patents.51 While the 
EU does not have classes of patents, it does preclude “the patenting of certain 
biotechnological inventions.” 52  Under EPC 52 (4) gene therapy patents are 
MEDICINE 1329 (1329); and David Keays, Article: Patenting DNA & Amino Acid Sequences—An 
Australian Perspective, 7 HEALTH L.J. 69 (1999).
47
 Enerson, supra note 44, 694 (citing Gerald Paterson, THE EUROPEAN PATENT SYSTEM: THE LAW 
AND PRACTICE OF THE EUROPEAN PATENT CONVENTION SECTIONS 1-12, at 3 (2d ed. 2001)).
48
 Keays, supra note 46, at 84; see generally Chambers, supra note 46.
49
 Chambers, supra note 46, at 232.
50 Id.
51 Id.
52 Id.
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prohibited “because they are not susceptible to industrial application.”53
Unlike the US system, the Article 53(a) of the EPC prohibits patents for 
inventions that are contrary to the morals of society.  This concept is called ordre 
public gives “automatic standing to concerned citizens, empowering them to 
challenge individual patents on the ground that issuance would be morally 
offensive and allowing the use of the judicial process to shape the law regulating 
bio tech patents.54  This type of standing, ordre public, is not available in the US.  
As the EU continued to fall ever further behind the US in biotechnological
innovations, Directive 98/44/EC was created “to protect inventor’s rights in 
certain biotechnological produces.”55
The current international patent regime
While there are several important regional patent treaties, I wish to 
address two treaties that are historical and function beyond mere regional 
treaties.  The first is the Paris Convention, which was signed in that late 1800s.  
This treaty is designed to give national treatment to foreign inventors who are 
residents of a member state.  In other words, an inventor in the UK, according to 
this treaty, would get the same treatment in France as a French resident.  This 
was a monumental step towards creating an international patent regime.  
The second main international treaty (created in the mid 1990s) is the 
Trade-Related Intellectual Property Rights Agreement (hereinafter “TRIPS”).  
53 Id.
54 Id. at 233.
55 Id. at 237.
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TRIPS provides that patents shall be available for any inventions, whether 
products or processes, in all fields of technology provided they are new, involve 
an inventive step (non-obvious) and are capable of industrial application (useful).
It is important to note at the onset that TRIPS in this regard is similar to the 
requirements of the EPC.  Therefore, it seems that the International community is 
currently following the EPC in this regard.
In addition, article 27 of TRIPS has a statutory moral utility doctrine, again 
similar to the EPC over against the US patent code.  Though US case law shows 
a general trend towards minimizing the US common law moral utility doctrine, 
cases minimizing the moral utility doctrine (such as Chakrabarty) were decided
before the passage of the TRIPS. Therefore, it remains to be seen if current US 
patent case law concerning minimizing the moral utility doctrine would remain 
valid in the face of the US’ ratification of TRIPS and its statutory moral utility 
doctrine.
Additionally, TRIPS, again like the EPC, allows patents for inventions.  
Therefore, it seems that what patent protection TRIPS does provide, resembles 
the EPC over against the US patent law system.  Finally, TRIPS like the EPC 
provides patents for “technological innovations.”  In other words, US business 
methods under the EPC and under TRIPS do not seem patentable, unless they 
are patents for technological innovations.
Finally, TRIPS utilizes like the EPC a patent system that has a first to file 
system, while the US has a first to invent system.  Therefor e, as it currently 
stands, TRIPS provides a minimal substantive international patenting regime that 
16
is more closely aligned with the EU system, rather than the US system.
Moving towards a universal international patenting regime.56
The EU, Japan, and the US are spearheading negotiations to create a 
world patent regime called the Substantive Patent Law Treaty that utilizes the
Patent Cooperation Treaty and the Patent Law Treaty.  This trinity likely will one 
day form a substantive world patent regime.  
The first of the tripartite patent regime, the Patent Cooperation Treaty 
(“PCT”) was created in 1970, amended in 1979, and modified in both 1984 and 
2001.57  The treaty is open to any state part of the Paris Convention.58  It 
currently is in force and has been since 1970.  Article one, section one of the 
PCT states that the treaty provides for “cooperation in the filing, searching and 
examination, of applications for the protection of inventions, and for rendering 
special technical services.”  Article 1, section 2 states that “No provision of this 
treaty shall be interpreted as diminishing the rights under the Paris Convention 
for the Protection of Industrial Property of any national or resident of any country 
party to that Convention.”  In essence, the Paris Convention gave national 
treatment to foreigners so long as they were residents of a state party to the 
56
 See id.; Shira Pridan-Frank, Article: Human-Genomics: A Challenge to the Rules of the Game 
of International Law, 40 Colum. J. Transnat’l L. 619 (2002); Diana D. McCall, Note: Stating the 
obvious: Patents and Biological Material, 2003 U. Ill. J.L. Tech. & Pol’y 239 (2003); James 
Bradshaw, Comment: Gene Patent Policy: Does issuing Gene Patents Accord with the Purposes 
of the U.S. Patent System?, 37 Willamette L. Rev 637 (2001); Trilateral Working Group: 
Substantive Harmonization of Patent Law (SPLT): The European Perspective, European Patent 
Office, Sept. 2003 (available from author);  Patent Reform (need to get form Yu’s site); WIPO 
website splt
57
 International Protection of Industrial Property: Patent Cooperation Treaty (“PCT”) (1970), 
available at: http://wipo.int/pct/en/treaty/about.htm).
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Paris Convention.  Therefore, the PCT clearly states that it does not add any 
rights apart from those already given.  In essence the PCT grants patent 
applicants a streamlined process in which they can do an international patent 
search for a fee.  The patent search does not guarantee the granting of patents 
with member states.  However, it does provide an additional 18 month grace 
period to the PCT patent applicant to decide whether to apply for patents around 
the world.
Before moving to the second treaty in the tripartite agreement, lets first 
consider how biotechnology in general and stem cells in particular would have 
been dealt with at this treaty apart from the later two components.   There are 
two important time zones pre-TRIPS and post-TRIPS.  Before the passage of 
TRIPS, the Paris Convention was the key intellectual property regime and as 
stated supra it invoked national treatment for applicants of member states.  This 
being said, stem cell research would have been accepted or denied per state 
according to whether the individual state granted patents on stem cell research.  
Nations at the forefront of biotechnological innovations, however, could pressure 
member states through bilateral agreements or through other more aggressive 
means.  Pressure coming from the United States, however, is very influential and 
likely to have lead to a positive result for the United States in regards to individual 
bilateral agreements with nations not as willing to accept the progressive 
biotechnological patenting agenda of the United States.  
It seems that Article 27 of TRIPS has provided a trump card for many 
58 Id.
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smaller nations with qualms about biotechnological patents: the statutory moral 
utility doctrine.  Furthermore, it seems that growing regional treaties such as the 
European Union and the European Patent Convention have provided the many 
smaller nations of Europe the bargaining power to match or even exceed that of 
the United States.  What this means, ultimately, is that regional agreements,
such as EPC, have provided greater, more cohesive opposition to the US 
biotechnological agenda.  However, this seems to have simplified things a little 
bit too much, as is evidenced by EU Directive 98/44/EC, which attempted to 
provide patenting protection for some biological inventions.  In essence however, 
it seems that pre-TRIPS the US would have had an easier time pushing its 
biotechnological patent agenda, rather than in the post-TRIPS world.
Now that we have examined the first tripartite, lets take a look at the 
second, the Patent Law Treaty. PLT currently is not in effect, primarily because 
40, mostly unindustrialized, nations have refused to sign it.  They are arguing for 
implementation of the Convention on Biological Diversity.59 If enacted the treaty 
would harmonize patent office formalities for the administration of patent 
applications.  This treaty makes clear in article three that it is not a substantive
patent law treaty, but rather that the provisions in the PLT apply to applications 
that are permitted in the Paris Convention and the PCT.  In other words, this 
treaty creates a uniform set of rules for patent applications to all countries that 
sign up.   Generally speaking, this treaty neither helps nor hinders the US 
biotechnological patent agenda.
59
 Grain, supra note 56. 
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However, the third tripartite in the developing world patent regime is the 
Substantive Patent Law Treaty (SPLT).  If negotiations go poorly for the US, then 
the US risks being excluded or having a world patent treaty that is extremely 
difficult for it to accept.  The main areas of concern for the United States continue 
to be a statutory moral utility doctrine that preempts granting patents to any
invention that adversely affects the ordre public or morals of a society.  The 
United States stands to lose too much if it allows negotiations to create a world 
patent regime that will not grant patents to the US’ prolific biotechnological 
industries.
The United States needs to show the EU that the statutory moral utility 
doctrine is very problematic.  As is shown by the diversity of responses of EU 
member states to biotechnology patents, EU member states that have similar 
histories can not even agree on what violates the ordre public.60  This is a very 
big problem.  If a group of nations with shared histories cannot agree on what is 
moral and what is not, then how can nations across the world?  The key problem, 
really, is that nations around the world do not fully realize that the United States 
has mechanisms outside the patenting regime that can keep science in a comfort 
zone of morality.  President Bush’s response to embryonic stem cell research is 
one such example.  Another example involves the Chimera case, where the court 
held that a patent could not be issued because it violated the post civil war 
amendments.
60
 Germany and Ireland and Italy do not allow many biotechnology patents, whereas the UK is 
rather progressive in this arena.  What is critical to note is that Germany has still failed to ratify 
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However, the United States may need to bend on other areas to allow for 
a world patent regime that is acceptable for all nations.  For instance the United 
States is practically the only nation in the world that has a first to invent system.  
While the rest of the world is concerned about the welfare of their societies in 
general, the United States seems concerned about the welfare of individuals in 
their society.  The United States does this by providing a first to invent system, as 
opposed to the procedurally much simpler first to file system.  The rest of the 
world can address the US concern of individual fairness by modifying the first to 
file system by adding a comfortable grace period for inventors to claim priority 
ahead of those who are first to file.
The United States needs to allow other nations to have the freedom to 
prevent the utilization of biotechnology patents that they feel violate the morals of 
their society.  Therefore, countries like Ireland, Italy and Germany according to 
such a proposition will recognize stem cell patents and other controversial 
biotechnology patents, but they will have the right to exclude the utilization of that 
patent within its borders.  In other words, they will have the right to prevent 
techniques that utilize these patents by deeming their use illegal within its 
borders.  This allows these more conservative countries to uphold the morals of 
their society, while at the same time protecting the intellectual property of other
foreign countries.
As we examined the EPC and US patent regime we saw that the US 
system was more flexible than the EPC.  The US needs to argue for a patenting 
the EU Directive on Biotechnology, despite pressure from member states, the United States, and 
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regime that is flexible, in much the same manner as the founding fathers 
establish the foundations for a flexible patenting regime.  The US system 
appears to have more readily responded to the challenges of biotechnology 
patents.  The EU system had too many hiccups and this is probably due more to 
the statutory moral utility doctrine, than anything else.
As stem cells have shown us vis-à-vis patents, any successful patenting 
system must be flexible and adaptable to changing and unforeseen technologies.  
Without a flexible patent system that is free from the shackles of a statutory 
moral utility doctrine, science and technology may be unnecessarily stunted.  
That being said the response of the US system to the metaphysical debate and 
the ethical considerations of stem cell research has shown that there are many 
avenues outside of a patenting regime that can be used to keep science and 
research within a healthy and acceptable parameter.
biotechnology industries within its borders.
